Neoadjuvant immunotherapy improves outlook in high-risk melanoma
Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who ...
Sep 11, 2022
0
39